Syncom Formulations (India) Ltd

Syncom Formul. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syncom Formulations (India) Ltd

₹ 20.0 1.32%
21 May - close price
syncomformulations.com BSE: 524470 NSE: SYNCOMF
About

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Key Points

Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]

Website BSE NSE
  • Market Cap ₹ 1,881 Cr.
  • Current Price ₹ 20.0
  • High / Low ₹ 27.9 / 11.0
  • Stock P/E 38.0
  • Book Value ₹ 3.64
  • Dividend Yield 0.00 %
  • ROCE 18.8 %
  • ROE 15.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Debtor days have improved from 118 to 84.4 days.

Cons

  • Stock is trading at 5.50 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 11.4% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
58 51 54 57 61 60 64 65 75 86 102 128 149
56 48 50 51 55 53 57 58 65 77 90 113 131
Operating Profit 2 3 4 6 6 6 6 7 9 9 12 15 18
OPM % 4% 7% 8% 10% 10% 11% 10% 11% 13% 11% 12% 12% 12%
6 3 3 2 7 2 4 5 3 2 4 4 7
Interest 1 0 1 1 1 1 1 1 1 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 1
Profit before tax 6 5 5 6 10 6 8 9 10 10 15 17 23
Tax % 16% 22% 33% 30% 18% 28% 23% 25% 26% 24% 25% 25% 24%
5 4 4 4 8 4 7 7 7 8 11 13 18
EPS in Rs 0.06 0.04 0.04 0.04 0.09 0.05 0.07 0.07 0.08 0.08 0.12 0.14 0.19
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025
115 151 173 184 185 216 222 262 465
104 135 155 167 168 196 202 232 411
Operating Profit 11 16 18 17 17 20 20 30 54
OPM % 9% 11% 11% 9% 9% 9% 9% 11% 12%
1 1 1 3 3 12 15 14 17
Interest 1 0 0 0 0 2 3 5 1
Depreciation 3 3 3 3 3 4 5 5 5
Profit before tax 8 14 16 16 16 26 27 34 66
Tax % 33% 33% 38% 36% 34% 24% 24% 25% 25%
6 9 10 10 11 20 20 25 49
EPS in Rs 0.07 0.12 0.13 0.13 0.13 0.23 0.21 0.27 0.53
Dividend Payout % 24% 17% 16% 15% 15% 13% 0% 0% 0%
Compounded Sales Growth
10 Years: 10%
5 Years: %
3 Years: 29%
TTM: 77%
Compounded Profit Growth
10 Years: 17%
5 Years: %
3 Years: 36%
TTM: 100%
Stock Price CAGR
10 Years: 17%
5 Years: 87%
3 Years: 31%
1 Year: 52%
Return on Equity
10 Years: %
5 Years: %
3 Years: 11%
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 22 78 78 78 78 86 94 94 94
Reserves 65 17 22 31 39 136 162 194 248
2 3 6 6 12 58 83 72 5
33 42 31 61 50 28 39 44 67
Total Liabilities 123 140 138 175 180 308 378 405 413
50 50 46 46 55 94 91 120 125
CWIP 0 0 0 5 0 6 26 0 0
Investments 7 9 6 23 36 43 64 66 93
66 80 85 101 89 165 197 219 196
Total Assets 123 140 138 175 180 308 378 405 413

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025
6 7 0 24 14 16 11 -6 23
-0 -4 1 -23 -18 -27 -45 83 -18
-6 -1 1 -2 5 8 35 -15 -68
Net Cash Flow -1 2 2 -1 1 -2 1 62 -63

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 92 71 66 91 91 114 124 144 84
Inventory Days 29 36 34 43 29 51 55 49 49
Days Payable 91 105 63 130 92 36 53 56 51
Cash Conversion Cycle 29 1 37 4 27 129 126 137 83
Working Capital Days 101 83 97 51 66 131 133 152 168
ROCE % 15% 16% 15% 13% 10% 11% 19%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.08% 0.09% 0.10% 0.13% 0.11%
49.43% 49.43% 49.43% 49.44% 49.44% 49.44% 49.44% 49.35% 49.34% 49.34% 49.30% 49.32%
No. of Shareholders 2,35,5172,32,7502,32,0692,27,4782,24,9252,24,2522,89,9823,25,7613,76,5304,69,2424,89,5204,84,529

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue